Evaluation of Romiplostim In a Randomized Placebo-Controlled Phase 3 Study of a Japanese Population with Chronic Immune Thrombocytopenia (ITP).

罗米普洛斯蒂姆 医学 安慰剂 血小板生成素 内科学 临床终点 人口 血小板 脾切除术 加药 随机对照试验 胃肠病学 病理 脾脏 替代医学 造血 环境卫生 生物 遗传学 干细胞
作者
Kôji Miyazaki,Yukari Shirasugi,Kiyoshi Ando,Yoshiaki Tomiyama,Shinichiro Okamoto,Mineo Kurokawa,Keita Kirito,Yuji Yonemura,Shin‐ichiro Mori,Kensuke Usuki,Koji Iwato,Satoshi Hashino,Helen Wei,Richard Lizambri
出处
期刊:Blood [American Society of Hematology]
卷期号:116 (21): 3704-3704 被引量:1
标识
DOI:10.1182/blood.v116.21.3704.3704
摘要

Abstract Abstract 3704 Introduction: Chronic immune thrombocytopenia (ITP) is an autoimmune disorder characterized by both increased platelet destruction and decreased platelet production. Romiplostim increases platelet counts by binding and activating the thrombopoietin receptor. Romiplostim has been approved for the treatment of adult ITP in the United States, Europe, Canada, and Australia. This study evaluated dosing, efficacy, and safety in a Japanese population of adults with ITP. Methods: This phase 3 study was placebo-controlled, double-blind, and randomized 2:1 (romiplostim:placebo). Patients were eligible for the study if they were Japanese patients with ITP diagnosed at least 6 months before the initial screening, were aged ≥ 20 years, and were H pylori negative or had received at least 1 treatment for H pylori eradication. Patients were stratified by splenectomy status (yes or no). After a 3-week evaluation period, patients were treated for 12 weeks with a weekly subcutaneous injection of either romiplostim or placebo. The starting dose was 3 mcg/kg with dose adjustments to a maximum of 10 mcg/kg to achieve a platelet count within the target range of ≥ 50 to ≤ 200 × 109/L. Patients were monitored posttreatment until their platelet count dropped to ≤ 50 × 109/L or for a maximum of 12 weeks. The primary endpoint was number of weeks with platelet response (platelet count ≥ 50 × 109/L). Results: Thirty-four patients enrolled (22 romiplostim, 12 placebo), 24 (71%) were female, the median (range) age was 55 (44 - 64) years, and the median (range) baseline platelet count was 19 (3 – 32) × 109/L. Patients had received a median of 4 (1 – 19) prior ITP therapies, and 15 (44%) had previously undergone a splenectomy; 23 (68%) patients were receiving concurrent ITP therapy at baseline. All patients completed the study. Romiplostim demonstrated superiority to placebo on weekly platelet response, incidence of increase in platelet count ≥ 20 × 109/L from baseline, change from baseline in mean of last 4 platelet counts during week 2 to week 13, and number of weeks with platelet counts within the target range (Table 1), and 16 (73%) romiplostim patients had platelet counts ≥ 200 × 109/L. Twenty-one (95%) patients in the romiplostim group had a platelet response with a median time of 1 week until first response. Results for weekly platelet response were comparable irrespective of splenectomy status and baseline concurrent ITP therapy. Two (17%) patients in the placebo group achieved a platelet response. In romiplostim-treated patients, posttreatment platelet counts remained > 50 × 109/L for 8 weeks in one and for 12 weeks in another. The mean weekly dose of romiplostim for the study was 2.6 mcg/kg compared with the dose range of 3–4 mcg/kg in prior phase 3 studies (Kuter et al. Lancet. 2008;371:395–403). There was a low incidence of rescue medication use in the study (Table 1). The adverse events profile was comparable to that seen in non-Japanese studies. Patients in both treatment groups experienced similar proportions of adverse events (91% romiplostim, 92% placebo). Adverse events with > 10% higher frequency in the romiplostim group than placebo group) were (romiplostim, placebo) nasopharyngitis (41%, 17%), headache (32%, 17%), peripheral edema (18%, 0%), back pain (14%, 0%), and pain in extremity (14%, 0%). Significant (≥ grade 3) bleeding events occurred in 1 patient in the romiplostim group (subarachnoid hemorrhage) and 1 patient in the placebo group (subarachnoid hemorrhage, cerebral hemorrhage, and gastrointestinal hemorrhage). There were no adverse events of bone marrow reticulin, thrombosis, or detection of neutralizing antibodies. Conclusion: Romiplostim significantly increased and maintained platelet counts and was well-tolerated in a Japanese ITP population. Disclosures: Tomiyama: Kyowa Hakko Kirin Co.: Speakers Bureau; GlaxoSmithKline: Speakers Bureau. Kurokawa:Novartis: Consultancy; Shionogi & Co., Ltd.: Consultancy. Wei:Amgen Inc.: Employment, Equity Ownership. Lizambri:Amgen Inc.: Employment, Equity Ownership.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
科研通AI2S应助Meidina采纳,获得10
1秒前
zzj512682701完成签到,获得积分10
2秒前
宋志远发布了新的文献求助10
2秒前
张祖伦完成签到 ,获得积分10
2秒前
张张呀发布了新的文献求助10
2秒前
2秒前
4秒前
一一应助rrfhl采纳,获得10
5秒前
Unihoranfider完成签到,获得积分10
6秒前
6秒前
小鱼爱吃肉应助顺利狗采纳,获得10
6秒前
yu发布了新的文献求助10
7秒前
harvey1989发布了新的文献求助10
10秒前
LL发布了新的文献求助10
11秒前
13秒前
15秒前
15秒前
Lucas应助Metastasis采纳,获得30
15秒前
llei应助俊逸的难破采纳,获得30
16秒前
脑洞疼应助追寻砖家采纳,获得10
16秒前
LL完成签到,获得积分10
17秒前
爱吃肥牛完成签到 ,获得积分10
17秒前
zho发布了新的文献求助10
18秒前
18秒前
宋志远发布了新的文献求助10
20秒前
yan完成签到,获得积分10
21秒前
lyon完成签到,获得积分10
22秒前
搜集达人应助无醇橙汁采纳,获得10
23秒前
椒盐柠檬茶完成签到,获得积分10
26秒前
张张呀发布了新的文献求助10
26秒前
不打扰完成签到 ,获得积分10
27秒前
nn完成签到 ,获得积分10
28秒前
小火锅完成签到,获得积分10
30秒前
31秒前
ChandlerZB完成签到,获得积分10
31秒前
31秒前
32秒前
emoji完成签到,获得积分10
34秒前
35秒前
高分求助中
The late Devonian Standard Conodont Zonation 2000
The Lali Section: An Excellent Reference Section for Upper - Devonian in South China 1500
Nickel superalloy market size, share, growth, trends, and forecast 2023-2030 1000
Smart but Scattered: The Revolutionary Executive Skills Approach to Helping Kids Reach Their Potential (第二版) 1000
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 800
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 800
A new species of Coccus (Homoptera: Coccoidea) from Malawi 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3245829
求助须知:如何正确求助?哪些是违规求助? 2889464
关于积分的说明 8258504
捐赠科研通 2557814
什么是DOI,文献DOI怎么找? 1386661
科研通“疑难数据库(出版商)”最低求助积分说明 650327
邀请新用户注册赠送积分活动 626685